BioVaxys Provides Update on Management Cease Trade Order

VANCOUVER, BC — April 13, 2026 — Leads & Copy — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) has issued a bi-weekly update regarding its management cease trade order (MCTO), initially granted on March 3, 2026, by the British Columbia Securities Commission (BCSC).

The MCTO was issued under National Policy 12-203, following the company's announcement on March 3, 2026, that it was unable to file its audited annual financial statements for the year ended October 31, 2025. This also included the related management’s discussion and analysis, and its Form 52-109FV1 CEO and CFO certifications of annual filings. These filings, collectively referred to as the “Annual Filings,” were required by February 28, 2026, under National Instrument 51-102.

BioVaxys is actively collaborating with its auditor, Dale Matheson Carr-Hilton LaBonte LLP, to finalize the Annual Filings, with the expectation of filing them as soon as possible. The company anticipates completing the Annual Filings by April 28, 2026, assuming current conditions remain stable.

As a consequence of the delay in filing the Annual Filings, BioVaxys anticipates a delay in filing its interim financial statements for the three months ended January 31, 2025, including the management’s discussion and analysis and related filings, collectively referred to as the “Interim Filings.” These filings were due by April 1, 2026, under National Instrument 51-102. The company plans to file the Interim Filings immediately following the completion of the Annual Filings.

The company confirms it is satisfying the provisions of the alternative information guidelines under NP 12-203 and will continue to issue bi-weekly default status reports via news releases while it remains in default with the Annual Filings and/or Interim Filings.

BioVaxys also stated that there is no information regarding any anticipated specified default subsequent to the default in filing the Annual Filings, and the company is not subject to any insolvency proceedings. Additionally, there is no other material information concerning the company's affairs that has not been generally disclosed.

The investing public can continue to trade BioVaxys' listed common shares freely while the MCTO is in effect. However, the MCTO prohibits the company’s CEO and CFO from trading securities of the company until the Annual Filings are completed. BioVaxys is also prohibited from directly or indirectly issuing or acquiring securities from insiders or employees until the Annual Filings have been made, all continuous disclosure requirements have been met, and the MCTO has been revoked.

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies. The company's technologies include the DPX™ immune-educating technology platform and the HapTenix© tumor cell construct platform, targeting cancers, infectious diseases, food allergies, and other immunological diseases. Its clinical pipeline includes maveropepimut-S (MVP-S) for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum-resistant Ovarian Cancer, as well as DPX™+SurMAGE, MVP-S+letrozole, DPX™-RSV, DPX+rPA, and BVX-0918.

BioVaxys common shares are listed on the CSE under the symbol “BIOV”, the Frankfurt Bourse (FSE: 5LB0), and the OTC Markets (OTCQB: BVAXF).

Source: BioVaxys Technology Corp.